Neville, Daniel
Ferguson, Daniel T.
Heikamp, Emily B.
Lai, Zhihao
Magor, Graham W.
Lam, Charlene
Dobbs, Olivia G.
Levina, Vita
Knezevic, Kathy
The, James J.
Alex, Shania
Suits, Stephen C.
Rumler, Bradon
Uckelmann, Michael
Talarmain, Laure
Lam, Enid Y. N. https://orcid.org/0000-0001-5843-7836
Perkins, Andrew C. https://orcid.org/0000-0003-3644-7093
Armstrong, Scott A. https://orcid.org/0000-0002-9099-4728
Bell, Charles C. https://orcid.org/0000-0003-2194-8311
Davidovich, Chen https://orcid.org/0000-0002-1085-6094
Gilan, Omer https://orcid.org/0000-0003-4156-2619
Funding for this research was provided by:
Victorian Cancer Agency (MCRF19040)
Department of Health | National Health and Medical Research Council (1146192)
Department of Health | National Health and Medical Research Council (APP1162921)
Department of Health | National Health and Medical Research Council (APP1184637)
Department of Health | National Health and Medical Research Council (APP2011767)
Department of Health | National Health and Medical Research Council (APP2020900)
Cancer Council Victoria
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08 CA279891)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA06516)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08 CA279891)
U.S. Department of Health & Human Services | National Institutes of Health (CA066996)
Article History
Received: 12 February 2024
Accepted: 15 December 2025
First Online: 3 February 2026
Competing interests
: S.A.A. has been a consultant and/or shareholder for Neomorph, Cyteir Therapeutics, C4 Therapeutics, Accent Therapeutics, Hyku Therapeutics and Stelexis Therapeutics. S.A.A. has received research support from Janssen, Novartis and Syndax. S.A.A. is an inventor on a patent related to MENIN inhibition WO/2017/132398A1. The other authors declare no competing financial interests.